erlotinib — CareFirst (Caremark)

Initial criteria

• Member has locally advanced, unresectable, recurrent, or metastatic pancreatic cancer
• Erlotinib is used in combination with gemcitabine

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on the current regimen

Approval duration

12 months